Access Oncology, Gem cancer deal

Access Oncology (New York, N.Y.) licensed from Gem Pharmaceuticals (Birmingham, Ala.) GPX-100 and GPX-150, 2 non-cardiotoxic analogs of doxorubicin to treat cancer. Gem will receive up to $33 million ...